Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline

British Journal of Haematology

Volumn 144, Issue 6, 2009, Pages 895-903

  Richardson, Paul G ^a   Sonneveld, Pieter ^b   Schuster, Michael W ^c   Stadtmauer, Edward A ^d   Facon, Thierry ^e   Harousseau, Jean Luc ^f   Ben Yehuda, Dina ^g   Lonial, Sagar ^h   Goldschmidt, Hartmut ⁱ   Reece, Donna ^j   Bladé, Joan ^k   Boccadoro, Mario ^l   Cavenagh, Jamie D ^m   Boral, Anthony L ⁿ   Esseltine, Dixie Lee ⁿ   Wen, Patrick Y ^a,o   Amato, Anthony A ^a,o   Anderson, Kenneth C ^a   San Miguel, Jesus ^p  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f HÔTEL DIEU   (France)

^g HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^h EMORY UNIVERSITY   (United States)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j PRINCESS MARGARET HOSPITAL   (Canada)

^k UNIVERSITY OF BARCELONA   (Spain)

^l UNIVERSITY OF TURIN   (Italy)

^m ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

ⁿ MILLENNIUM PHARMACEUTICALS INC   (United States)

^o MASSACHUSETTS GENERAL HOSPITAL   (United States)

^p Centro de Investigacion del Cancer   (Spain)

more..

Author keywords

Bortezomib; Dose modification; Multiple myeloma; Peripheral neuropathy; Relapsed

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; CARNITINE; DULOXETINE; FOLIC ACID; GABAPENTIN; GLYCOSYLATED HEMOGLOBIN; NORTRIPTYLINE; THALIDOMIDE; THIOCTIC ACID; VINCA ALKALOID; VITAMIN; VITAMIN B COMPLEX;

ADULT; ARTICLE; CANCER RELAPSE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NUTRITIONAL SUPPORT; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CLINICAL PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; RECURRENCE; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 60749125815     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07573.x     Document Type: Article

References (33)

1. Adams, J. (2004) The proteasome: a suitable antineoplastic target. Nature Reviews. Cancer, 4, 349 360.
2. Bladé, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115 1123.
3. Calhoun, E.A., Fishman, D.A., Roland, P.Y., Lurain, J.R., Chang, C. Cella, D. (2000) Validity and selective sensitivity of the FACT-GOG Ntx. Journal of Clinical Oncology, 19, 446a.
4. Casellini, C.M. Vinik, A.I. (2007) Clinical manifestations and current treatment options for diabetic neuropathies. Endocrine Practice, 13, 550 566.
5. Cavaletti, G., Gilardini, A., Canta, A., Rigamonti, L., Rodriguez-Menendez, V., Ceresa, C., Marmiroli, P., Bossi, M., Oggioni, N., D'Incalci, M. De Coster, R. (2007) Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Experimental Neurology, 204, 317 325.
6. Cella, D.F., Tulsky, D.S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S.B., Winicour, P. Brannon, J. (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. Journal of Clinical Oncology, 11, 570 579.
7. Chen, C.I., Kouroukis, C.T., White, D., Voralia, M., Stadtmauer, E., Stewart, A.K., Wright, J.J., Powers, J., Walsh, W. Eisenhauer, E. (2007) Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 25, 1570 1575.
8. Dispenzieri, A. Kyle, R.A. (2005) Neurological aspects of multiple myeloma and related disorders. Best Practice & Research. Clinical Haematology, 18, 673 688.
9. Fisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O'Connor, O.A., Shi, H., Boral, A.L. Goy, A. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 24, 4867 4874.
10. Hausheer, F.H., Schilsky, R.L., Bain, S., Berghorn, E.J. Lieberman, F. (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology, 33, 15 49.
11. Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P.G., Niesvizky, R., Alexanian, R., Limentani, S.A., Alsina, M., Adams, J., Kauffman, M., Esseltine, D.L., Schenkein, D.P. Anderson, K.C. (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal of Haematology, 127, 165 172.
12. Jagannath, S., Barlogie, B., Berenson, J.R., Siegel, D.S., Irwin, D., Richardson, P.G., Niesvizky, R., Alexanian, R., Limentani, S.A., Alsina, M., Esseltine, D.L. Anderson, K.C. (2008) Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. British Journal of Haematology, 143, 537 540.
13. Kelly, Jr., J.J., Kyle, R.A., Miles, J.M., O'Brien, P.C. Dyck, P.J. (1981) The spectrum of peripheral neuropathy in myeloma. Neurology, 31, 24 31.
14. Krarup-Hansen, A., Helweg-Larsen, S., Schmalbruch, H., Rorth, M. Krarup, C. (2007) Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain, 130, 1076 1088.
15. Pal, P.K. (1999) Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyography and Clinical Neurophysiology, 39, 323 330.
16. Plasmati, R., Pastorelli, F., Cavo, M., Petracci, E., Zamagni, E., Tosi, P., Cangini, D., Tacchetti, P., Salvi, F., Bartolomei, I., Michelucci, R. Tassinari, C.A. (2007) Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology, 69, 573 581.
17. Popat, R., Oakervee, H.E., Hallam, S., Curry, N., Odeh, L., Foot, N., Esseltine, D.L., Drake, M., Morris, C. Cavenagh, J.D. (2008) Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. British Journal of Haematology, 141, 512 516.
18. Rajkumar, S.V., Blood, E., Vesole, D., Fonseca, R. Greipp, P.R. (2006) Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 24, 431 436.
19. Rajkumar, S.V., Rosinol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J.B. Blade, J. (2008) Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. Journal of Clinical Oncology, 26, 2171 2178.
20. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 2609 2617.
21. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487 2498.
22. Richardson, P.G., Briemberg, H., Jagannath, S., Wen, P.Y., Barlogie, B., Berenson, J., Singhal, S., Siegel, D.S., Irwin, D., Schuster, M., Srkalovic, G., Alexanian, R., Rajkumar, S.V., Limentani, S., Alsina, M., Orlowski, R.Z., Najarian, K., Esseltine, D., Anderson, K.C. Amato, A.A. (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Journal of Clinical Oncology, 24, 3113 3120.
23. Richardson, P.G., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San Miguel, J., Bladé, J., Boccadoro, M., Cavenagh, J., Alsina, M., Rajkumar, S.V., Lacy, M., Jakubowiak, A., Dalton, W., Boral, A., Esseltine, D.-L., Schenkein, D. Anderson, K. (2007a) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood, 110, 3557 3560.
24. Richardson, P.G., Chanan-Khan, A., Lonial, S., Krishman, A., Carroll, M., Cropp, G.F., Kersey, K., Abitar, M., Johnson, R.G., Hannah, A.L. Anderson, K.C. (2007b) Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): confirmation of the recommended dose using a novel formulation. Blood, 110, 353a.
25. Richardson, P.G., Xie, W., Mitsiades, C., Chanan-Khan, A.A., Lonial, S., Hassoun, H., Avigan, D.E., Oaklander, A.L., Kuter, D.J., Wen, P.Y., Kesari, S., Briemberg, H.R., Schlossman, R.L., Munshi, N.C., Heffner, L.T., Doss, D., Esseltine, D.-L., Weller, E., Anderson, K.C. Amato, A.A. (2009) Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. Journal of Clinical Oncology in press).
26. Ropper, A.H. Gorson, K.C. (1998) Neuropathies associated with paraproteinemia. New England Journal of Medicine, 338, 1601 1607.
27. San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.-V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H. Richardson, P.G. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906 917.
28. Silverman, L., Csizmadia, V., Kadambi, V.J., Decoster, R., Vynckier, A., Jortner, B. Alden, C.J. (2006) Model for proteasome inhibition associated peripheral neuropathy. Toxicologic Pathology, 34, 989.
29. Silverman, L., Csizmadia, V., Brewer, K., Simpson, C. Alden, C. (2008) Proteasome inhibitor associated neuropathy is mechanism based. Blood, 112, abstract 2646.
30. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565 1571.
31. Treon, S.P., Hunter, Z.R., Matous, J., Joyce, R.M., Mannion, B., Advani, R., Cook, D., Songer, J., Hill, J., Kaden, B.R., Sharon, D., Steiss, R., Leleu, X., Branagan, A.R. Badros, A. (2007) Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clinical Cancer Research, 13, 3320 3325.
32. Vrethem, M., Cruz, M., Wen-Xin, H., Malm, C., Holmgren, H. Ernerudh, J. (1993) Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. Journal of the Neurological Sciences, 114, 193 199.
33. Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E.A., Siegel, D., Borrello, I., Rajkumar, S.V., Chanan-Khan, A.A., Lonial, S., Yu, Z., Patin, J., Olesnyckyj, M., Zeldis, J.B. Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine, 357, 2133 2142.